Takeda Pharmaceutical (TAK) News Today → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free TAK Stock Alerts $13.05 -0.23 (-1.73%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineA Five-Pillar Process To Develop Sales Leadersforbes.com - May 8 at 7:27 AMTakeda Pharmaceutical's Fourth-Quarter Profit Expected to Have More Than Tripled -- Earnings Previewmarketwatch.com - May 8 at 7:27 AMTakeda Pharmaceutical (TAK) to Release Earnings on Thursdayamericanbankingnews.com - May 8 at 6:34 AMTakeda Pharmaceutical (TAK) Set to Announce Earnings on Thursdaymarketbeat.com - May 2 at 10:00 AMY.D. More Investments Ltd Has $17.90 Million Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)marketbeat.com - May 1 at 4:50 PMBeacon Biosignals and Takeda Launch Strategic Collaboration to Advance Neurobiomarkers and Endpoints for Sleep Disordersfinance.yahoo.com - April 30 at 5:48 PMabrdn plc Takes Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)marketbeat.com - April 30 at 4:59 AMTakeda Pharmaceutical Company Limited (NYSE:TAK) Short Interest Down 26.5% in Aprilmarketbeat.com - April 27 at 4:15 PMTakeda Reports Positive CHMP Opinion For Fruquintinib - Quick Factsmarkets.businessinsider.com - April 26 at 9:56 AMTakeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancerbusinesswire.com - April 26 at 8:30 AMFederated Hermes Inc. Has $6.26 Million Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)marketbeat.com - April 26 at 5:39 AMTakeda said to have left industry trade group BIOmsn.com - April 25 at 6:54 PMTakeda Pharmaceutical (NYSE:TAK) Reaches New 12-Month Low at $13.08marketbeat.com - April 25 at 3:45 PMJapan’s SMBC joins JV to support drug discovery start-upsmsn.com - April 24 at 12:47 PMNeurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorderfinance.yahoo.com - April 23 at 8:02 AMTakeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programsprnewswire.com - April 22 at 4:10 AMExploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In Pharmaceuticalsbenzinga.com - April 19 at 2:33 PMU.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Diseasefinance.yahoo.com - April 18 at 7:31 PMU.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Diseasebusinesswire.com - April 18 at 7:00 PMTakeda Pharmaceutical Company Limited (4502.T)finance.yahoo.com - April 16 at 10:32 PMTakeda Pharmaceutical (NYSE:TAK) Hits New 52-Week Low at $13.19marketbeat.com - April 15 at 5:31 PMTakeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Foodbusinesswire.com - April 8 at 8:00 AMPacer Advisors Inc. Sells 897,979 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)marketbeat.com - April 6 at 4:32 AMTakeda Pharmaceutical Company Limited (NYSE:TAK) is XY Capital Ltd's 3rd Largest Positionmarketbeat.com - April 4 at 9:25 PMOncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory Boardbusinesswire.com - April 2 at 9:18 PMAculys Pharma Announces Appointment of Hidemasa Tanigaki as New CEOfinance.yahoo.com - April 1 at 3:15 AMTakeda Pharmaceutical (NYSE:TAK) Trading Down 2.4%marketbeat.com - March 28 at 5:39 PMPuerto Rico Declares Dengue Epidemic as Cases Climbusnews.com - March 28 at 3:27 PMEmpathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAEprnewswire.com - March 27 at 8:53 AMTakeda Announces Candidates for Board of Directors at Upcoming Shareholders Meetingbusinesswire.com - March 26 at 7:07 PMTakeda Announces Approval Of ADZYNMA Intravenous Injection 1500 In Japanmarkets.businessinsider.com - March 26 at 9:07 AMTakeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)finance.yahoo.com - March 26 at 9:07 AMThe Leadership Development Group Releases Guide on Talent Management Strategies For Post-Milestone Growthfinance.yahoo.com - March 21 at 10:57 AMTakeda : FDA Approves SNDA For Iclusig In Adult Patients With Newly Diagnosed Ph+ ALLmarkets.businessinsider.com - March 19 at 11:52 PMTakeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALLbusinesswire.com - March 19 at 12:20 PMAdvanced Infusion Care (AIC) Now Offers Takeda's GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] and ARALAST® NP [Alpha1-Proteinase Inhibitor (Human)]businesswire.com - March 18 at 6:12 AMTakeda Pharmaceuticals: Takeda's 'In Their Shoes' Program Sheds Light on IBD Challenges in South Africafinanznachrichten.de - March 15 at 3:29 PMTakeda Pharmaceutical Company Limited (NYSE:TAK) Short Interest Updatemarketbeat.com - March 14 at 3:35 PMProstate Cancer - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033finance.yahoo.com - March 13 at 2:30 PMTakeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopeniafinance.yahoo.com - March 13 at 9:30 AMMercer Global Advisors Inc. ADV Grows Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)marketbeat.com - March 11 at 7:59 AM136,100 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Bought by Schonfeld Strategic Advisors LLCmarketbeat.com - March 8 at 6:26 AMQube Research & Technologies Ltd Reduces Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)marketbeat.com - March 7 at 5:51 AMTakeda Pharmaceutical: Eohilia's FDA Approval Brings Tailwindsseekingalpha.com - March 5 at 12:38 PMFive things: Takeda's big lease, more biotech cuts, Ted Williams' jersey and a basketball bandwagonbizjournals.com - March 5 at 7:38 AMTakeda staying in Kendall Squaremsn.com - March 4 at 9:19 PMTakeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profitsseekingalpha.com - March 3 at 8:44 AMFmr LLC Buys 115,947 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)marketbeat.com - March 2 at 5:20 AMTakeda and India's Biological E. to accelerate access to dengue vaccine in endemic areasmsn.com - February 27 at 8:20 AMJapan's Takeda partners with India's Biological E. to boost dengue vaccine productionreuters.com - February 27 at 1:07 AM Get Takeda Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. Email Address BREAKING – Pentagon to Spend $20 Billion on “Distributed AI” (Ad)BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it. Discover the name and ticker of this $2 stock here >>> TAK Media Mentions By Week TAK Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TAK News Sentiment▼0.320.36▲Average Medical News Sentiment TAK News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TAK Articles This Week▼45▲TAK Articles Average Week Get Takeda Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GMAB News Today ALNY News Today TEVA News Today BMRN News Today BGNE News Today VTRS News Today KRTX News Today RDY News Today SRPT News Today UTHR News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:TAK) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Company Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
